FDA approves J&J’s RYBREVANT for NSCLC treatment
2024-03-04
临床3期上市批准临床结果加速审批优先审批
Preview
来源: Pharmaceutical Technology
The decision upgrades the May 2021 accelerated approval to full approval for Johnson & Johnson’s RYBREVANT regimen. Credit: JHVEPhoto / Shutterstock.com.
The US Food and Drug Administration (FDA) has granted full approval for Johnson & Johnson‘s (J&J) RYBREVANT (amivantamab-vmjw) plus chemotherapy for non-small cell lung cancer (NSCLC) patients.
This decision, which comes after a priority review, upgrades the May 2021 accelerated approval to full approval.
RYBREVANT is indicated for use in combination with carboplatin-pemetrexed chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC harbouring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The latest development is based on data from the open-label, randomised Phase III PAPILLON clinical trial of RYBREVANT in combination with chemotherapy.
It assessed the safety and efficacy of the combination regimen, as opposed to chemotherapy alone, in newly diagnosed patients.
See Also:Amylyx Pharmaceuticals files patent for treatment for neurodegenerative disease using bile acid and phenylbutyrate
Preview
来源: Pharmaceutical Technology
ORIC Pharmaceuticals files patent for PLK4 inhibitorsPLK4 inhibitors for cancer treatment
Preview
来源: Pharmaceutical Technology
Progression-free survival (PFS) was the trial’s primary endpoint. Secondary endpoints included objective response rate (ORR), PFS after the first succeeding therapy, overall survival (OS) and time to symptomatic progression.
The combination of RYBREVANT and chemotherapy led to a 61% reduction in the disease progression or mortality risk versus chemotherapy alone.
Results indicated an improvement in ORR and PFS for patients treated with the RYBREVANT regimen.
J&J innovative medicine, solid tumours and clinical development vice-president Kiran Patel stated: “We are redefining care for patients with non-small cell lung cancer by advancing innovative regimens that can be used early, to extend survival.
“RYBREVANT plus chemotherapy is the first targeted approach approved for the first-line treatment of patients with NSCLC with EGFR exon 20 insertion mutations. We look forward to building on this latest milestone as we continue to accelerate our transformative lung cancer portfolio.”
The latest development follows FDA approval of J&J’s supplemental biologics licence application for TECVAYLI (teclistamab-cqyv), allowing for a reduced dosing frequency for relapsed or refractory multiple myeloma patients.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。